



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 94,778-H-CO)

In application of:)	
)	
Tryggvason et al.)	Examiner :
)	
Serial No. 10/733,698)	Group Art Unit:
)	
Filed: December 11, 2003)	Confirmation No.:
)	
For: Laminin Chains: Diagnostic and)	
Therapeutic Uses)	

TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
 - a) Information Disclosure Statement
 - b) Form PTO/SB/08
 - c) Return postcard
2. With respect to fees:
 - a) No fee is required at this time.
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. **CERTIFICATE OF MAILING UNDER 37 CFR § 1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 20th day of **April 2004**.

Respectfully submitted,



David S. Harper
Registration No. 42,636



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 94,778-H-CO)

In application of:)	
)	
Tryggvason et al.)	Examiner :
)	
Serial No. 10/733,698)	Group Art Unit:
)	
Filed: December 11, 2003)	Confirmation No.:
)	
For: Laminin Chains: Diagnostic and)	
Therapeutic Uses)	

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Pursuant to 37 C.F.R. §1.98(d), copies of references numbered 1-22 are not provided herewith, since they were previously filed in the parent applications.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

U.S. Patent Documents


1. 5,152,980 10-06-1992 Strom et al.

Other Documents

2. Pikkarainen et al., *Eur. J. Biochem*, 209:571-582 (1991).
3. Pikkarainen et al., *J. Biol. Chem.*, 263:6751-6758 (1988).
4. Pikkarainen et al., *J. Biol. Chem.*, 262:10454-10462 (1987).
5. Vuolteenaho et al., *J. Cell. Biol.*, 124:381-394 (1994).
6. Hudson et al., *J. Biol. Chem.*, 268:26033-26036 (1993).
7. Tryggvason, *Current Opinion in Cell Biol*, 5:877-882 (1993).
8. Kallunki et al., *J. Biol. Chem.*, 119:679-693 (1992).
9. Pyke et al., *Am. J. Pathol.*, 145:1-10 (1994).
10. Burgeson et al., *Matrix Biology*, 14:209-211 (1994).
11. Pulkkinen et al., *Nature Genetics*, 6(3):293-297 (Mar. 1994).
12. Aberdam et al., *Nature Genetics*, 6:299-304 (1994).
13. Embase Abstract No.: 97163048 (1997).
14. Snyder et al., "λgt 11: Gene Isolation with Antibody Probes and Other Applications," *Methods in Enzymology*, 154:107-128 (1987).
15. Hao et al., "Differential Expression of Laminin 5 (α3β3γ2) by Human Malignant and Normal Prostate," *Am. J. Pathol.*, 149(4):1341-1349 (1996).
16. Matsui et al., "γ² Chain of Laminin-5 is Recognized by Monoclonal Antibody GB3," *J. Invest. Dermatol.*, 105(5):648-652 (1995).
17. Pyke et al., "The γ² Chain of Kalinin/Laminin 5 is Preferentially Expressed in Invading Malignant Cells in Human Cancers," *Am. J. Pathol.*, 145(4):782-791 (Oct. 6, 1994).
18. Pyke et al., "Laminin-5 is a Marker of Invading Cancer Cells in Some Human Carcinomas...", *Cancer Res.*, 55:4132-4139 (1995).
19. Verrando et al., "Nicein (BM600) in Junctional Epidermolysis Bullosa: Polyclonal Antibodies Provide New Clues for Pathogenic Role," *J. Invest. Dermatol.*, 101(5):738-743 (1993).
20. Verrando et al., "Monoclonal Antibody GB3 Defines a Widespread Defect of Several Basement Membranes...", *Lab. Invest.*, 64(1):85-92 (1991).
21. Wewer et al., "Selective Assembly of Laminin Variants by Human Carcinoma Cells," *Lab. Invest.*, 71(5):719-730 (Nov. 1994).
22. Marinkovich et al., *J. Biol. Chem.*, 267(25):17900-17906 (2000).

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Date: April 20, 2004

By: 
David S. Harper
Registration No. 42,636

Please type a plus sign (+) inside this box C



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application No.	10/733,698
				Filing Date:	December 11, 2003
				First Named Inventor	Tryggvason
				Group Art Unit	
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket No.	94,778-H-CO

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		PIKKARAINEN ET AL., <i>Eur. J. Biochem</i> , 209:571-582 (1991).	
		PIKKARAINEN ET AL., <i>J. Biol. Chem.</i> , 263:6751-6758 (1988).	
		PIKKARAINEN ET AL., <i>J. Biol. Chem.</i> , 262:10454-10462 (1987).	
		VUOLTEENAHO ET AL., <i>J. Cell. Biol.</i> , 124:381-394 (1994).	
		HUDSON ET AL., <i>J. Biol. Chem.</i> , 268:26033-26036 (1993).	
		TRYGGVASON, <i>Current Opinion in Cell Biol</i> , 5:877-882 (1993).	
		KALLUNKI ET AL., <i>J. Biol. Chem.</i> , 119:679-693 (1992).	
		PYKE ET AL., <i>Am. J. Pathol.</i> , 145:1-10 (1994).	
		BURGESSON ET AL., <i>Matrix Biology</i> , 14:209-211 (1994).	
		PULKKINEN ET AL., <i>Nature Genetics</i> , 6(3):293-297 (Mar. 1994).	
		ABERDAM ET AL., <i>Nature Genetics</i> , 6:299-304 (1994).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Please type a plus sign (+) inside this box ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application No.	10/733,698
				Filing Date:	December 11, 2003
				First Named Inventor	Tryggvason
				Group Art Unit	
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket No.	94,778-H-CO

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Embase Abstract No.: 97163048 (1997).	
		SNYDER ET AL., "λgt 11: Gene Isolation with Antibody Probes and Other Applications," <i>Methods in Enzymology</i> , 154:107-128 (1987).	
		HAO ET AL., "Differential Expression of Laminin 5 (α3β3γ2) by Human Malignant and Normal Prostate," <i>Am. J. Pathol.</i> , 149(4):1341-1349 (1996).	
		MATSUI ET AL., "γ ² Chain of Laminin-5 is Recognized by Monoclonal Antibody GB3," <i>J. Invest. Dermatol.</i> , 105(5):648-652 (1995).	
		PYKE ET AL., "The γ ² Chain of Kalinin/Laminin 5 is Preferentially Expressed in Invading Malignant Cells in Human Cancers," <i>Am. J. Pathol.</i> , 145(4):782-791 (Oct. 6, 1994).	
		PYKE ET AL., "Laminin-5 is a Marker of Invading Cancer Cells in Some Human Carcinomas...", <i>Cancer Res.</i> , 55:4132-4139 (1995).	
		VERRANDO ET AL., "Nicein (BM600) in Junctional Epidermolysis Bullosa: Polyclonal Antibodies Provide New Clues for Pathogenic Role," <i>J. Invest. Dermatol.</i> , 101(5):738-743 (1993).	
		VERRANDO ET AL., "Monoclonal Antibody GB3 Defines a Widespread Defect of Several Basement Membranes...", <i>Lab. Invest.</i> , 64(1):85-92 (1991).	
		WEWER ET AL., "Selective Assembly of Laminin Variants by Human Carcinoma Cells," <i>Lab. Invest.</i> , 71(5):719-730 (Nov. 1994).	
		MARINKOVICH ET AL., <i>J. Biol. Chem.</i> , 267(25):17900-17906 (2000).	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231